Mycoplasma Testing Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	180 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19260780

Best Price Guarantee
Price	from $4,850
Length	180 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19260780

Mycoplasma Testing Market

Growth Factors of Mycoplasma Testing Market

The mycoplasma testing market size was valued at USD 843.1 billion in 2022, and the market is now projected to grow from USD 883.5 billion in 2023 to USD 1,251.6 billion by 2030, exhibiting a CAGR of 5.1% during the forecast period of 2023-2030.

A moderate impact from COVID-19 led to a rise in the installation of mycoplasma testing systems during projected period. The COVID-19 pandemic is having a negative influence on people all around the world, and because of the abrupt lockdown, it has also ultimately disrupted production at manufacturing facilities. Citing a number of secondary sources, the decreased installation of mycoplasma testing and labor shortages caused roughly 45% of mycoplasma testing companies in the United States to lose their seasonal sales. A number of sectors suffered during the coronavirus pandemic and had significant declines until the latter part of 2020. The energy recovery ventilator market is somewhat unaffected by this, given that ventilation is required in many different areas. As a result, the market saw only minor effects from the pandemic and is expected to quickly rebound during the forecast period. Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the market switched to treating covid patients as priority over the other procedures which led the mycoplasma testing market growth.

Increasing R&D efforts in a range of healthcare environments to drive the need for testing products during projected period. Moreover, the utilization of these testing kits and reagents by researchers and laboratory staff is increasing as a result of increased awareness of bacterial contamination and rigorous adherence to the regulations to prevent these contaminations in laboratories and research organizations.

Growing collaboration among industry participants to merge technology and skill sets promote mycoplasma testing market growth during projected period. As a result of the growing need for innovative products and technologies for mycoplasma contamination testing, industry participants are focusing more on working together to launch cutting-edge goods. An increasing number of product approvals and launches by market players are a result of researchers' increased concern in labs and academic institutes to avoid or eradicate mycoplasma infection in cell cultures. In order to meet the growing demand for these items among healthcare researchers, pharmaceutical companies and other healthcare institutions are benefiting from the deployment of technology that increases the efficiency of test kits and processes along with reduced turnaround times.

Comprehensive Analysis of Mycoplasma Testing Market

The mycoplasma testing market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by Testing Method, by product, by application and by end users. The Testing Method segmentations include Culture-based, PCR-based, and Others and by Product segmentations include Instruments and Reagents & Kits, By Application segmentations include Virus Testing, Vaccine Testing, Cell Culture, and Others. However, the end users segmentations include Cell banks, Contract Research Organizations & Contract Manufacturing Organizations, Biopharmaceutical & Biotechnology Companies, and others.

The North America region lead the mycoplasma testing market by benefitting a market size of USD 411.5 million in 2023 because governments, regulatory bodies, and other healthcare organizations worldwide are making more efforts and funding more research initiatives in order to develop and distribute drugs and vaccines.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These prominent players include, Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Lonza (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Sartorius AG (Germany), bioMérieux SA (France) and Asahi Kasei Corporation (Japan), these market players provide a level-playing competitive environment across the globe.

In April 2023, flourishing its biologics manufacturing capability, Bionova Scientific, a biopharmaceutical CDMO with headquarters in the United States, is bolstering its research endeavors.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Growth Rate CAGR of 5.1% from 2023 to 2030

Unit Value (USD Million)

Segmentation By Testing Method

PCR-based

Culture-based

Others

By Product

Instruments

Reagents & Kits

By Application

Cell Culture

Vaccine Testing

Virus Testing

Others

By End-user

Biopharmaceutical & Biotechnology Companies

Cell banks

Contract Research Organizations & Contract Manufacturing Organizations

Others

By Region

North America (By Testing Method, Product, Application, End-user, and By Country)

U.S. (By Testing Method)
Canada (By Testing Method)

Europe (By Testing Method, Product, Application, End-user, and Country/Sub-region)

U.K. (By Testing Method)
Germany (By Testing Method)
France (By Testing Method)
Italy (By Testing Method)
Spain (By Testing Method)
Rest of Europe (By Testing Method)

Asia Pacific (By Testing Method, Product, Application, End-user, and Country/Sub-region)

China (By Testing Method)
Japan (By Testing Method)
India (By Testing Method)
Australia (By Testing Method)
Southeast Asia (By Testing Method)
Rest of Asia Pacific (By Testing Method)

Rest of the World (By Testing Method, Product, Application, and End-user)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Overview of R&D Expenditure, Key Regions/Key Countries, 2022; 4.2. Technological Advancements in Mycoplasma Testing; 4.3. Key Industry Developments – Mergers, Acquisitions & Partnership; 4.4. New Product Launches; 4.5. Impact of COVID-19 on the Market
5. Global Mycoplasma Testing Market Analysis, Insights and Forecast, 2019-2030: 5.1. Market Analysis, Insights and Forecast – By Testing Method; 5.1.1. PCR-based; 5.1.2. Culture-based; 5.1.3. Others; 5.2. Market Analysis, Insights and Forecast – By Product; 5.2.1. Instruments; 5.2.2. Reagents & Kits; 5.3. Market Analysis, Insights and Forecast – By Application; 5.3.1. Cell Culture; 5.3.2. Vaccine Testing; 5.3.3. Virus Testing; 5.3.4. Others; 5.4. Market Analysis, Insights and Forecast – By End User; 5.4.1. Biopharmaceutical & Biotechnology Companies; 5.4.2. Cell banks; 5.4.3. Contract Research Organizations & Contract Manufacturing Organizations; 5.4.4. Others; 5.5. Market Analysis, Insights and Forecast – By Region; 5.5.1. North America; 5.5.2. Europe; 5.5.3. Asia Pacific; 5.5.4. Rest of the World
6. North America Mycoplasma Testing Market Analysis, Insights and Forecast, 2019-2030: 6.1. Market Analysis, Insights and Forecast – By Testing Method; 6.1.1. PCR-based; 6.1.2. Culture-based; 6.1.3. Others; 6.2. Market Analysis, Insights and Forecast – By Product; 6.2.1. Instruments; 6.2.2. Reagents & Kits; 6.3. Market Analysis, Insights and Forecast – By Application; 6.3.1. Cell Culture; 6.3.2. Vaccine Testing; 6.3.3. Virus Testing; 6.3.4. Others; 6.4. Market Analysis, Insights and Forecast – By End User; 6.4.1. Biopharmaceutical & Biotechnology Companies; 6.4.2. Cell banks; 6.4.3. Contract Research Organizations & Contract Manufacturing Organizations; 6.4.4. Others; 6.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 6.5.1. U.S.; 6.5.1.1. By Testing Method; 6.5.2. Canada; 6.5.2.1. By Testing Method
7. Europe Mycoplasma Testing Market Analysis, Insights and Forecast, 2019-2030: 7.1. Market Analysis, Insights and Forecast – By Testing Method; 7.1.1. PCR-based; 7.1.2. Culture-based; 7.1.3. Others; 7.2. Market Analysis, Insights and Forecast – By Product; 7.2.1. Instruments; 7.2.2. Reagents & Kits; 7.3. Market Analysis, Insights and Forecast – By Application; 7.3.1. Cell Culture; 7.3.2. Vaccine Testing; 7.3.3. Virus Testing; 7.3.4. Others; 7.4. Market Analysis, Insights and Forecast – By End User; 7.4.1. Biopharmaceutical & Biotechnology Companies; 7.4.2. Cell banks; 7.4.3. Contract Research Organizations & Contract Manufacturing Organizations; 7.4.4. Others; 7.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 7.5.1. U.K; 7.5.1.1. By Testing Method; 7.5.2. Germany; 7.5.2.1. By Testing Method; 7.5.3. France; 7.5.3.1. By Testing Method; 7.5.4. Spain; 7.5.4.1. By Testing Method; 7.5.5. Italy; 7.5.5.1. By Testing Method; 7.5.6. Rest of Europe; 7.5.6.1. By Testing Method
8. Asia Pacific Mycoplasma Testing Market Analysis, Insights and Forecast, 2019-2030: 8.1. Market Analysis, Insights and Forecast – By Testing Method; 8.1.1. PCR-based; 8.1.2. Culture-based; 8.1.3. Others; 8.2. Market Analysis, Insights and Forecast – By Product; 8.2.1. Instruments; 8.2.2. Reagents & Kits; 8.3. Market Analysis, Insights and Forecast – By Application; 8.3.1. Cell Culture; 8.3.2. Vaccine Testing; 8.3.3. Virus Testing; 8.3.4. Others; 8.4. Market Analysis, Insights and Forecast – By End User; 8.4.1. Biopharmaceutical & Biotechnology Companies; 8.4.2. Cell banks; 8.4.3. Contract Research Organizations & Contract Manufacturing Organizations; 8.4.4. Others; 8.5. Market Analysis, Insights and Forecast – By Country/ Sub-region; 8.5.1. Japan; 8.5.1.1. By Testing Method; 8.5.2. China; 8.5.2.1. By Testing Method; 8.5.3. India; 8.5.3.1. By Testing Method; 8.5.4. Australia; 8.5.4.1. By Testing Method; 8.5.5. Southeast Asia; 8.5.5.1. By Testing Method; 8.5.6. Rest of Asia Pacific; 8.5.6.1. By Testing Method
9. Rest of the World Mycoplasma Testing Market Analysis, Insights and Forecast, 2019-2030: 9.1. Market Analysis, Insights and Forecast – By Testing Method; 9.1.1. PCR-based; 9.1.2. Culture-based; 9.1.3. Others; 9.2. Market Analysis, Insights and Forecast – By Product; 9.2.1. Instruments; 9.2.2. Reagents & Kits; 9.3. Market Analysis, Insights and Forecast – By Application; 9.3.1. Cell Culture; 9.3.2. Vaccine Testing; 9.3.3. Virus Testing; 9.3.4. Others; 9.4. Market Analysis, Insights and Forecast – By End User; 9.4.1. Biopharmaceutical & Biotechnology Companies; 9.4.2. Cell banks; 9.4.3. Contract Research Organizations & Contract Manufacturing Organizations; 9.4.4. Others
10. Competitive Analysis: 10.1. Global Market Share Analysis (2022); 10.2. Company Profiles; 10.2.1. Merck KGaA; 10.2.1.1. Overview; 10.2.1.2. Product; 10.2.1.3. SWOT Analysis; 10.2.1.4. Recent Developments; 10.2.1.5. Strategies; 10.2.1.6. financials (Based on Availability); 10.2.2. Thermo Fisher Scientific Inc.; 10.2.2.1. Overview; 10.2.2.2. Product; 10.2.2.3. SWOT Analysis; 10.2.2.4. Recent Developments; 10.2.2.5. Strategies; 10.2.2.6. financials (Based on Availability); 10.2.3. F. Hoffmann-La Roche Ltd.; 10.2.3.1. Overview; 10.2.3.2. Product; 10.2.3.3. SWOT Analysis; 10.2.3.4. Recent Developments; 10.2.3.5. Strategies; 10.2.3.6. financials (Based on Availability); 10.2.4. Sartorius AG; 10.2.4.1. Overview; 10.2.4.2. Product; 10.2.4.3. SWOT Analysis; 10.2.4.4. Recent Developments; 10.2.4.5. Strategies; 10.2.4.6. financials (Based on Availability); 10.2.5. Asahi Kasei Corporation; 10.2.5.1. Overview; 10.2.5.2. Product; 10.2.5.3. SWOT Analysis; 10.2.5.4. Recent Developments; 10.2.5.5. Strategies; 10.2.5.6. financials (Based on Availability); 10.2.6. Biomeriux SA; 10.2.6.1. Overview; 10.2.6.2. Product; 10.2.6.3. SWOT Analysis; 10.2.6.4. Recent Developments; 10.2.6.5. Strategies; 10.2.6.6. financials (Based on Availability); 10.2.7. Charles River Laboratories; 10.2.7.1. Overview; 10.2.7.2. Product; 10.2.7.3. SWOT Analysis; 10.2.7.4. Recent Developments; 10.2.7.5. Strategies; 10.2.7.6. financials (Based on Availability); 10.2.8. ATCC; 10.2.8.1. Overview; 10.2.8.2. Product; 10.2.8.3. SWOT Analysis; 10.2.8.4. Recent Developments; 10.2.8.5. Strategies; 10.2.8.6. financials (Based on Availability); 10.2.9. Other Prominent Players